VC-backed Mersana Therapeutics debuts IPO
Cambridge, Massachusetts-based biotech company Mersana Therapeutics has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading June 28, 2017 on the NASDAQ under the ticker symbol "MRSN." JP Morgan, Cowen and Leerink Partners are the lead underwriters. Mersana's backers included Cormorant Asset Management, Arrowpoint Partners, Takeda Pharmaceutical Company Limited, New Enterprise Associates and Rock Springs Capital.
28 June 2017•2 mins read
